Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Slump In Generic Submissions Helps US FDA Draw Nearly Even With Approvals

Executive Summary

ANDA approval rates have remained steady, while submission rates dropped compared to prior years.

You may also be interested in...



FDA Avoided Half Of ANDA Pre-Approval Inspections During COVID By Using Alternative Tools

Records reviews are common now in lieu of an in-person inspection for US generic applications, but more virtual facility checks could be coming soon.

Remote Site Visits Will Help US FDA Keep Reviews On Track During Remainder Of Pandemic

Video facility tours expected to help clear way for timely drug and biologic approvals while COVID-19 still prevents inspections.

ANDA Sponsors Could Lose Exclusivity Because COVID-19 Prevented An Inspection … Or Not

US FDA will determine on a case-by-case basis whether its inability to inspect a facility because of the pandemic could result in 180-day exclusivity forfeiture for first generic filers.

Related Content

Topics

UsernamePublicRestriction

Register

PS144184

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel